

Meetings

Prostaglandins in Fertility Control

There is a rapidly increasing interest in the use of prostaglandins for fertility control. Only 15 months have passed since the publication of the first reports from Sweden and Uganda describing the abortifacient effect of certain prostaglandins. During this period, exploratory clinical trials were initiated in a number of centers in Canada, Great Britain, Sweden, Uganda, United States, and Yugoslavia. All these centers were represented at a workshop conference on prostaglandins in fertility control, which was sponsored by the World Health Organization Research and Training Centre on Human Reproduction at Karolinska Institutet, Stockholm, and held 8 to 10 March 1971.

Until recently, shortage of supplies of prostaglandins was a major factor limiting research on prostaglandins. The availability of synthetic prostaglandins can be expected to change this situation significantly, and it may be anticipated that in the near future a large number of investigators in many countries will begin clinical studies of prostaglandins in fertility control.

In view of these several considerations, the organizing committee convened the clinical investigators who were engaged in this field, in order to provide an opportunity for the exchange of information, for delineating areas of agreement and disagreement, and for discussing ways and means of accelerating development.

In an introductory paper, Dr. S. Bergström (Sweden) gave a brief review of the chemistry, physiology, and pharmacology of this group of ubiquitously occurring hormonal compounds.

Introductory reviews were also given of the basic principles of planning multicenter trials of fertility-regulating agents by C. Tietze (United States) and of monitoring side effects by M. Vessey (Great Britain).

N. Wijkvist (Sweden) reviewed the smooth muscle-stimulating properties of the prostaglandins that are of fundamental importance for their use as abortifacients.

Frequent and intense uterine contractions can be induced by the intravenous infusion of PGE₁, PGE₂, and PGF_{2α} during the menstrual cycle as well as during the first two trimesters of gestation. Coordinated and effective uterine contractions do not appear until 3 to 6 hours after the start of the infusion. The intrauterine pressure developed in the early pregnant uterus during prostaglandin infusion is very high compared to that in the midpregnant uterus.

It was reported by E. Coutinho (Brazil) that the intravenous injection of PGF_{2α} stimulates the motility of the human tube in vivo, whereas PGE₂ has an inhibitory effect. Whether the effect of prostaglandins on tubal motility is involved in their antifertility effect remains to be established.

At the time of the conference, clinical experience with the induction of abortion by intravenous administration of PGF_{2α} and PGE₂ was limited to approximately 600 cases, that is, approximately 300 cases with each of the two compounds. Reports on the effect of PGF_{2α} were given by S. Karim (Uganda); M. Bygdeman and N. Wijkvist (Sweden); C. H. Hendricks, G. G. Anderson, F. Naftolin, R. J. Pion, E. J. Quilligan, and R. L. Vande Wiele (United States); J. M. Beazley, G. M. Filshie, and K. Hillier (Great Britain); R. Nyberg (Sweden); L. Andolsek (Yugoslavia).

It is difficult to compare the results of the various investigators because of the great differences in the protocols followed. Thus there was a considerable variation in the doses administered and the infusion periods employed. In most cases the number of subjects studied by a single investigator did not exceed ten. Considerably larger series were reported from Great Britain, Sweden, and Uganda. In some of these studies, a fixed dose regimen was followed, in others, the doses were increased until adequate uterine contractions were obtained. In some series, the infusion time

was limited to 8 hours, in others, it was continued up to 48 hours. A total of 158 complete or incomplete abortions were reported in 300 trials. The dose range necessary for abortion with PGF_{2α} was 50 to 100 μg/min.


Only six investigators reported on the intravenous infusion of PGE₂ for the induction of abortion. In these series, 204 of 298 subjects were reported not to have required subsequent surgical intervention. Approximately ten times less PGE₂ (5 to 10 μg/min) than PGF_{2α} (50 to 100 μg/min) was needed to induce abortion. The time reported for a successful termination varied from 7 to 36 hours. Although PGE₂ appeared to have a somewhat higher "success rate" than PGF_{2α} it was apparent that the data presented did not permit assessment of the advantages and disadvantages of PGF_{2α} as compared to PGE₂ nor of one protocol as compared to another. On the other hand, the limited experience indicates that both PGF_{2α} and PGE₂ are superior in their effect to PGE₁.

Intravenous administration of prostaglandins in the higher doses used often produced distressing side effects. Nausea, vomiting, and diarrhea were frequent side effects with doses of PGF_{2α} greater than 50 μg/min. Erythema or phlebitis (or both) at the infusion site was common with PGE₂. Headache, pyrexia, tachycardia, arrhythmia, and blurring of vision was reported in a number of cases (mainly from the U.S. group). In addition, three cases of hypotension and collapse were reported. Great differences in individual tolerance were noted.

The studies conducted in the United States followed protocols designed more as a tolerance study to evaluate side effects of stepwise increasing doses, and larger amounts were administered than those found sufficient, in the experience of other investigators, to induce abortion.

A total of 60 cases were reported by M. Bygdeman and N. Wijkvist (Sweden) and M. P. Embrey (Great Britain) in which PGF_{2α} and PGE₂ had been administered at intervals of 1 to 2 hours extraamniotically into the uterine cavity through a thin, indwelling catheter. The prostaglandin was given over periods ranging from 7 to 24 hours. PGF_{2α} was used in doses ranging from 250 to 750 μg and PGE₂ in doses between 50 and 200 μg. Of the 60 trials, 46 were reported to have resulted in complete abortion. The total dose required for induction

Measure Calories QUICKLY • ACCURATELY • CONVENIENTLY



with a fully automatic
PARR® Adiabatic Calorimeter

... and a PARR®
Digital Thermometer



Parr now offers a completely new oxygen bomb calorimeter for measuring the calorific or Btu value of coal, oil, jet fuels, foods and other solid or liquid samples.

A new solid-state automatic temperature controller eliminates all time consuming temperature adjustments, doubles the output and improves the repeatability in calorimetric tests.

A new Parr Digital Thermometer and Printer add speed, convenience and accuracy to any bomb calorimeter by displaying temperatures in bright, easily seen numbers readable to .001° C, and producing a printed record of all readings taken during a calorific test.

Ask for our latest calorimeter catalog.



PARR INSTRUMENT COMPANY
211 Fifty-Third St. Moline, Ill. 61265
Telephone (309) 762-7716


Circle No. 81 on Readers' Service Card

Revco is More than a freezer... It's a System.

You get more than dependable ULTra-low® temperature when you buy a Revco freezer. We adapt the freezer to your particular use through the proper accessories from our inventory control systems. Let us show you how Revco provides the total answer to your ULTra-low® temperature needs. Available in sizes from 1-1/2 to 25 cubic feet, including the standard 6.5, 9, 12 and 17 cubic foot sizes, in chest models and upright.

REVCO, INC.

1177 Memorial Drive
West Columbia, S.C. 29169
Tel. (803) 796-1700



The world's leader in ULTra-low® temperature equipment

Circle No. 80 on Readers' Service Card

ing abortion by this route was generally less than 5 and 3 mg, respectively; that is, approximately 5 percent of that required by intravenous administration. The incidence of generalized side effects was low compared to that seen after intravenous administration. Apart from some nausea and pain associated with the contractions, no vomiting or diarrhea was reported. Although the disadvantage of an indwelling catheter was recognized, it was agreed that the apparent advantage of administering prostaglandins locally at the site of action encourages further exploration of this route of administration, especially in the second trimester as an alternative to treatment with hypertonic salt solution.


It had been established that prostaglandins are absorbed from the vagina both in monkeys and humans. S. Karim (Uganda) reported on the vaginal administration of prostaglandins. After being given intravaginally 20 and 50 mg of PGE₂ and PGF_{2α}, respectively, every 4 hours, in a small volume for one or two consecutive days, 56 of 60 cases (6 to 23 weeks pregnant) were reported as "successes." Side effects similar to those occurring during systemic administration were reported in approximately 25 percent of the trials. There was a consensus of opinion that the prostaglandins administered vaginally exert their action after absorption into the systemic circulation. It is likely therefore that the efficacy and side effects of vaginally administered prostaglandins will be similar to those produced by similar concentrations in the plasma of intravenously infused prostaglandins.

In a limited number of cases prostaglandins were administered *intravaginally* or *intravenously* 3 to 7 days after the first missed period (S. Karim, N. Wiquist, and M. Bygdeman). The efficiency of the method could not be assessed on the basis of these preliminary trials. In several cases pregnancy continued, and repeated administrations were required. The possibility of effects on fetal development makes it essential to follow each case closely.

The effect of prostaglandins in infra-human primates was reviewed by G. Duncan (United States). Of special interest are the results of studies in which pregnancies in rhesus monkeys were successfully terminated with prostaglandins (PGE₂, PGF_{2α}, and 15-methyl-PGF_{2α}) given by the vaginal route. In contrast to the situation in humans, the conceptus is not expelled in the rhesus monkey after the administra-

If you use any of these gases

**SEND FOR NEW
SPECIALTY GASES
& EQUIPMENT CATALOG
FROM AIR PRODUCTS**



Acetylene	Deuterium	Iodine Pentafluoride	1,3 Pentadiene
Air	Dimethylamine	Isobutane	Perfluorobutene-2
Allene	Dimethyl Ether	Isobutylene	Perfluoropropane
Ammonia	2,2-Dimethylpropane	Krypton	Phosgene
Argon	Doping Gases		Phosphine
			Phosphorus Pentafluoride
Boron Trichloride	Ethane	Methane	Propane
Boron Trifluoride	Ethyl Acetylene	Methyl Acetylene	Propylene
Bromine Pentafluoride	Ethyl Chloride	Methyl Bromide	
Bromine Trifluoride	Ethyl Fluoride	2-Methylbutene-1	Research Grade Gases
Bromotrifluoroethylene	Ethylene	2-Methylbutene-2	
1,3 Butadiene	Ethylene Oxide	3-Methylbutene-1	Silane
Butane		Methyl Chloride	Silicon Tetrafluoride
1-Butene	Fluorine	Methyl Fluoride	Sulfur Dioxide
cis-2-Butene		Methyl Mercaptan	Sulfur Hexafluoride
trans-2-Butene	Halocarbon—	Monoethylamine	Sulfur Tetrafluoride
	11, 12, 13, 13B1,	Monomethylamine	Sulfuryl Fluoride
cis- and trans-2-Butene	14, 21, 22, 23, 113,	Neon	Tetrafluorohydrazine
Carbon Dioxide	114, 114B2, 115,	Nickel Carbonyl	Trifluoromethyl iodide
Carbon Monoxide	116, 142B, 152A,	Nitric Oxide	Trimethylamine
Carbonyl Fluoride	C-318, 1132A	Nitrogen	
Carbonyl Sulfide	Helium	Nitrogen Dioxide	Vinyl Bromide
Carrier Gases	Hexafluoropropene	Nitrogen Trifluoride	Vinyl Chloride
Chlorine	Hydrogen	Nitrogen Trioxide	Vinyl Fluoride
Chlorine Trifluoride	Hydrogen Bromide	Nitrosyl Chloride	Vinyl Methyl Ether
Chlorotrifluoroethylene	Hydrogen Chloride	Nitrous Oxide	
Cyanogen	Hydrogen Fluoride	Oxygen	Xenon
Cyclopropane	Hydrogen Iodide		Zero Gases
	Hydrogen Sulfide		

... Plus customer specified gas mixtures and a complete line of regulators, valves, flowmeters and other accessory equipment.

(Detach and mail this convenient order form today)

Air Products and Chemicals, Inc.
Specialty Gas Department
733 W. Broad Street, Emmaus, Pennsylvania 18049

Please send new 104-page Specialty Gases and Equipment Catalog No. 5068 listing the industry's largest selection of specialty gases, gas mixtures, and gas handling equipment . . . available nationally from convenient stock points and 65 district offices.

Name/Title _____

Company _____

Address _____

City/State _____ Zip _____

 **Air Products and Chemicals**
INC.

Total Capability and Product Integrity

tion of prostaglandins. Termination of pregnancy induced by prostaglandins in such animals is associated with heavy vaginal bleeding. Observable side effects are virtually nonexistent. There is a rapid decrease in circulating "progestin" in the plasma after administration of prostaglandin in early pregnancy. This seems to suggest a direct effect of prostaglandin on steroidogenic function of the corpus luteum in this species.

Recent progress in the metabolism and analysis of prostaglandins was described by B. Samuelsson (Sweden). This work provided information on the initial step in the biological inactivation of prostaglandins and on the time course of the appearance of metabolites in plasma. The results are of importance for more detailed pharmacokinetic studies, the design of analogs of prostaglandins and the development of methods for quantitation of plasma prostaglandins. A new method by which individual prostaglandins can be identified and determined quantitatively in extracts of body fluids in subnanogram quantities by means of a combination of gas chromatography and mass spectrometry with an isotope carrier technique was described.

The recent elucidation of the principal urinary metabolites of the primary prostaglandins has made it possible to obtain the first estimates of the amounts of prostaglandins formed in the human species. The figures reported for PGE₁ plus PGE₂ were 20 to .50 µg per 24 hours in women and 100 to 200 µg per 24 hours in men. Radioimmunoassays for prostaglandins have also been described; however, the specificity of these assay methods remains to be established. Cross reaction with various circulating metabolites appears to be a major problem. Such metabolites are formed very rapidly and occur in the plasma in larger amounts than the parent compounds.

The interactions between prostaglandins and steroid hormones are being studied by several investigators [Anderson and Vande Wiele (United States), Bygdeman and Wiqvist (Sweden)]. Under the experimental conditions used, the intravenous administration of prostaglandins did not affect the concentrations of estrogens, progesterone, or 17α-hydroxyprogesterone in the peripheral plasma.

However, it was reported by Vande Wiele that the infusion of prostaglandin resulted in a marked decrease in chorionic gonadotrophin in the plasma. This decrease occurred within a few

hours after the start of the infusion and was not accompanied by changes in concentrations of steroids. The mechanism of action by which prostaglandins diminish circulating HCG levels is incompletely understood at present.

While the potential of prostaglandins in fertility control is considerable it was obvious to all participants that present information on the properties and effects of the prostaglandins as fertility-regulating agents is still too limited to warrant indiscriminate clinical trials outside of carefully controlled studies in hospital facilities. The importance of fundamental research as a necessary prerequisite for later applied studies also emerged from the review of the current state of knowledge on prostaglandins for fertility control. It was agreed that exploration of the potential of the prostaglandins in the regulation of human fertility would be accelerated if a number of common clinical protocols including the administration of various prostaglandins in different ways, and the design of comparative trials with other fertility-regulating methods could be agreed upon internationally. Even such a fundamental question as the definition of a successful abortion (complete or incomplete) has not been uniform in all studies reported. Under a common protocol the results from different centers could be compared and a consensus based on a sufficient number of cases could be reached more quickly.

The participants of the conference indicated their willingness to participate in such collaborative studies.

It was also felt that international collaboration in the form of coordinated metabolic studies on various types of patients treated according to these protocols would be of great value. It was concluded that another, more specialized meeting was needed during the autumn of 1971 to discuss the various methodological problems and metabolic studies. The participants also agreed that the creation of an international task force would complement efforts now under way and would help to establish guidelines for clinical trials that may be expected to expand rapidly once prostaglandins become readily available.

The suggestion was made and approved that the World Health Organization Research and Training Centre on Human Reproduction at Karolinska Institutet should take the initiative in convening a task force for initiating such studies.

A second meeting of a smaller group




For a good look... TRY Bausch & Lomb's DynaZoom Flat Field Microscope

With the exclusive, extra value, Flat Field integrated optical system that gives you edge-to-edge sharp focus, full area images at all magnifications but at no extra cost.

Try one and let your own eyes decide. Write for catalog 31-185 and our free demonstration offer.

DynaZoom. Reg. T.M. Bausch & Lomb

Circle No. 31 on Readers' Service Card

BAUSCH & LOMB 

SCIENTIFIC INSTRUMENT DIVISION
20803 Bausch Street, N.Y. 14602

was convened at the same place on 25 and 26 August 1971. After a review of the new experience gained in the meantime, two protocols for intra-uterine administration (extra- and intraamniotic) were agreed upon for preliminary evaluation during a 4-month period. These and other clinical results as well as various analytical methods will be discussed at a third meeting organized by the Centre in January 1972.

S. BERGSTRÖM, E. DICZFALUSY
U. BORELL, S. KARIM
B. SAMUELSSON, B. UVNAS
N. WIKVIST, M. BYGDEMAN

World Health Organization Research and Training Centre on Human Reproduction, Karolinska Institutet, Stockholm, Sweden

Forthcoming Events

April

17-19. Society of **Economic Paleontologists and Mineralogists**, Denver, Colo. (Mrs. R. Tener, P.O. Box 979, Tulsa, Okla. 74101)

17-19. American Assoc. of **Petroleum Geologists**, Denver, Colo. (N. C. Smith, Box 979, Tulsa, Okla. 74101)

17-20. **Atomic and Molecular Physics** Conf., 4th, Sussex, England. (Meetings Officer, Inst. of Physics, 47 Belgrave Sq., London SW1X 8QX)

17-20. **Medical Advisers in the Pharmaceutical Industry**, intern. conf., London, England. (W. L. Burland, Conf. Management, 29 Old Bond St., London, W.1)

17-20. **Seed Ecology**, Loughborough, England. (W. Heydecker, School of Agriculture, University of Nottingham, Sutton Bonington, Loughborough, LE12 5RD)

17-21. **Dosimetry** Techniques Applied to Agriculture, Industry, Biology, and Medicine, Intern. Atomic Energy Agency, Prague, Czechoslovakia. (J. H. Kane, Div. of Technical Information, U.S. Atomic Energy Commission, Washington, D.C. 20545)

17-21. **Inner Shell Ionization Phenomena**, intern. conf., Atlanta, Ga. (R. W. Fink, School of Chemistry, Georgia Inst. of Technology, Atlanta 30332)

18-21. **Acoustical** Sec. of America, Buffalo, N.Y. (Miss B. H. Goodfriend, ASA, 335 E. 45 St., New York 10017)

19-21. **RNA in the Immune Response**, New York Acad. of Sciences, New York, N.Y. (W. Likely, NYAS, 2 East 63 St., New York 10021)

19-22. **International Communication** Assoc., Atlanta, Ga. (M. S. MacLean, Jr., Univ. of Iowa, Iowa City 52240)

20-22. **Louisiana Acad. of Sciences**, Baton Rouge. (B. F. Dowden, Dept. of Biological Sciences, Louisiana State Univ., Shreveport 71105)

20-22. **Ohio Acad. of Science**, Mari-

etta. (J. H. Melvin, OAS, 445 King Ave., Columbus)

20-22. American Assoc. of Colleges of **Pharmacy**, Houston, Tex. (C. W. Bliven, AACP, 850 Sligo Ave., Silver Spring, Md. 20910)

20-23. Cooper **Ornithological** Soc., Las Cruces, N.M. (W. H. Behle, Dept. of Biology, Univ. of Utah, Salt Lake City, 84112)

21-22. **Iowa Acad. of Science**, Iowa City. (R. W. Hanson, Dept. of Chemistry, Univ. of Northern Iowa, Cedar Falls 50613)

21-22. North Carolina **Acad. of Science**, Greenville. (J. G. Boyette, Dept. of Biology, East Carolina Univ., Greenville, 27834)

21-22. **Modern Optics**, American Physical Soc., New York State Section, Poughkeepsie, N.Y. (D. T. Teaney, IBM Research Center, P.O. Box 218, Yorktown Heights, N.Y. 10598)

22. American Soc. of **Hospital Pharmacists**, Houston, Tex. (J. A. Oddis, 4630 Montgomery Ave., Bethesda, Md. 20014)

22-28. American **Pharmaceutical** Assoc., Houston, Tex. (W. S. Apple, APA, 2215 Constitution Ave., NW, Washington, D.C.)

23-24. Congress on **Environmental Health**, American Medical Assoc., Los Angeles, Calif. (F. W. Barton, Council on Environmental and Public Health, 535 N. Dearborn St., Chicago, Ill. 60610)

23-26. Association of American **Geographers**, Kansas City, Kan. (J. W. Nystrom, AAG, 1146 16th St., NW, Washington D.C. 20036)

23-26. American **Oil Chemists' Soc.**, Los Angeles, Calif. (J. C. Lyon, 508 S. 6 St., Champaign, Ill. 61820)

23-28. American Soc. for **Microbiology**, Philadelphia, Pa. (R. W. Sarber, ASM, 1913 Eye St., NW, Washington, D.C. 20006)

24-26. **Communications Satellite Systems**, 4th conf., American Inst. of Aeronautics and Astronautics, Washington, D.C. (W. L. Prichard, COMSAT Labs., Box 115, Clarksburg, Md. 20734)

24-26. **Speech Communications and Processing**, Inst. of Electrical and Electronics Engineers, Inc., Boston, Mass. (W. D. Chapman, IBM Corp., P.O. Box 12275, Dept. E82, Bldg. 060, Research Triangle Park, N.C. 27709)

24-26. **Frontiers in Education**, Inst. of Electrical and Electronics Engineers, Inc., Tucson, Ariz. (IEEE, 345 E. 47 St., New York 10017)

24-26. **Reactor Materials Performance**, American Nuclear Soc., Richland, Wash. (T. T. Claudson, Pacific Northwest Lab., Battelle Memorial Inst., P.O. Box 999, Richland 99352)

24-27. **Chemical Vapor Deposition**, American Nuclear Soc., Salt Lake City, Utah. (F. A. Glaski, Fansteel Inc., 10258 Norris Ave., Pacoima, Calif. 91331)

24-27. American **Physical** Soc., Washington, D.C. (W. W. Havens, Jr., APS, 335 E. 45 St., New York 10017)

24-28. Society of **Manufacturing Engineers**, Chicago, Ill. (R. W. Taylor, 20501 Ford Rd., Dearborn, Mich. 48128)

plenum
PUBLISHING CORPORATION

RESEARCH METHODS IN NEUROCHEMISTRY VOLUME 1

Edited by **Neville Marks, N.Y.S. Research Inst. for Neurochemistry and Drug Addiction, Ward's Island, N.Y. and Richard Rodnight, Inst. of Psychiatry, London, England**

The introductory volume to this new continuing series is based on the actual research experience of the contributors, and it treats the following subject areas: ultrastructure and fragmentation of neural tissue, properties of intact neural tissue, cerebral constituents, and biologically active amines.

Many of the described methods represent innovations in the field of methodology pertaining to brain research, and findings are largely directed to investigators with a chemical or biochemical background.

Approx. 358 pages
ISBN 0-306-36001-2

June 1972
\$18.50

VASCULAR MECHANISMS OF THE BRAIN

By **G. I. Mchedlishvili, Georgian Academy of Sciences, Tbilisi, USSR**

A thorough study of the function and role of the vascular mechanisms of the brain in the regulation and pathology of cerebral circulation, this concise, comprehensive work embraces physical, histological, histochemical, and comparative morphological studies, among others. Excellent critical summaries of recent work in the field are also included.

98 pages February 1972 ISBN 0-306-10870-4
\$25.00

plenum press / consultants bureau

Divisions of Plenum Publishing Corporation
227 W. 17th ST., NEW YORK, NEW YORK 10011

Circle No. 83 on Reader's Service Card